Complete report spread across [60] pages available @ http://www.chinamarketresearchreports.com/114758.html .
The collection of ‘Energy & Power’ market research reports has a new addition of “Research Report on China Coke Industry, 2014-2018”On chinamarketresearchreports.com . Coke is widely used in the fields of blast furnace ironmaking, cupola iron melting, ferroalloy smelting and nonferrous metals smelting. As a reducing agent, energy source and carbon agent, coke is also used as a raw material in carbide production, gasification and synthetic chemistry. Statistics shows that over 90% of the global coke production is used in blast furnace ironmaking, for which metallurgic coke is one of the essential raw materials. Metallurgic coke is named as the "Basic Food" of the steel industry with important strategic value and economic significance. Coke industry in China can be divided into two categories based on the production structure. One category is professional manufacturers of commercial machine coke while the other one is coke manufacturers owned by largescale iron and steel enterprises. Coke produced by largescale iron and steel enterprises is usually not for sale but used by themselves. Therefore, only products of professional machine coke enterprises are available on the market. Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.
Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter. Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.
